Has results × Carcinoma, Renal Cell × Bevacizumab × Clear all A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase 2 Completed
83 enrolled 17 charts
IMmotion151
Phase 3 Completed
915 enrolled 40 charts
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Phase 2 Completed
41 enrolled 13 charts
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 1/2 Completed
60 enrolled 11 charts
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Phase 2 Completed
57 enrolled 10 charts
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Phase 2 Completed
52 enrolled 5 charts
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Phase 2 Completed
26 enrolled 11 charts
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
Phase 3 Terminated
77 enrolled 11 charts
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
361 enrolled 12 charts
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
59 enrolled 12 charts
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Phase 2 Completed
30 enrolled 12 charts
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Phase 2 Completed
41 enrolled 9 charts
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Phase 2 Completed
34 enrolled 9 charts
5-AZ
Phase 1/2 Terminated
11 enrolled 10 charts
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Phase 2 Terminated
10 enrolled 14 charts
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Phase 2 Completed
365 enrolled 14 charts
Bevacizumab in Metastatic Renal Cancer
Completed
365 enrolled 9 charts
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Phase 3 Completed
649 enrolled 18 charts
INTORACT
Phase 3 Completed
791 enrolled 11 charts
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Completed
37 enrolled 6 charts
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Phase 2 Terminated
8 enrolled 10 charts
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
19 enrolled 9 charts
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 2 Terminated
5 enrolled 10 charts
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Phase 2 Completed
146 enrolled 13 charts
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Phase 2 Completed
25 enrolled 8 charts
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 1/2 Terminated
5 enrolled 7 charts
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
Phase 2 Terminated
30 enrolled 18 charts
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Phase 1/2 Completed
94 enrolled 7 charts
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Phase 2 Terminated
16 enrolled 5 charts